Novartis inks deal to make Mass General Brigham’s COVID-19 vaccine candidate Reuters May 28, 2020 AveXis, which makes Novartis’s $2.1 million-per-patient gene therapy Zolgensma for the hereditary disease spinal muscular atrophy,…
